ANI Pharmaceuticals, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. ANI develops, manufactures, and markets generic, established-brand, and rare-disease pharmaceuticals. Its rare-disease business currently consists of Cortrophin Gel.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net revenue | $116.5 million | $73.9 million | $223.3 million | $138.3 million |
| Operating income (loss) | $12.4 million | $(12.9) million | $22.3 million | $(32.1) million |
| Net income (loss) | $6.2 million | $(14.9) million | $7.7 million | $(35.1) million |
| Basic EPS | $0.30 | $(0.94) | $0.36 | $(2.21) |
| Operating cash flow | — | $42.1 million | $(30.4) million |
- Q2 revenue rose 57.8%; six-month revenue rose 61.4%. Growth reflected higher generic volumes and launches, higher established-brand and services revenue, and increased Cortrophin Gel sales.
- Q2 revenue by category: generics $63.3 million; established brands, royalties, and services $28.9 million; rare disease $24.3 million. Cortrophin Gel revenue increased from $10.2 million to $24.3 million year over year in Q2.
- Cost of sales, excluding depreciation and amortization, was 36.3% of revenue in Q2 versus 47.8% a year earlier, and 35.8% for the first half versus 50.3%. Management attributed the improvement to product mix and the absence of prior-year acquired-inventory charges, among other factors.
- Q2 operating margin was 10.6%, versus negative 17.5% a year earlier. Six-month operating margin was 10.0%, versus negative 23.2%. Higher selling, general, and administrative costs and R&D partly offset revenue and cost-mix improvements.
- Cash and cash equivalents were $161.7 million at June 30, 2023, compared with $48.2 million at year-end 2022. Current assets were $459.3 million and current liabilities $122.9 million.
- Gross principal debt was $295.5 million; balance-sheet debt, net of financing costs, was approximately $286.1 million. The term-loan interest rate was 11.15%; $40 million remained available under the undrawn revolving facility, subject to conditions. The term loan matures in 2027.
Material changes and financing
- ANI raised $80.6 million net in a May 2023 public offering of 2.18 million common shares, increasing the share count. Proceeds are intended for business, product, and technology investments, commercialization, and general corporate purposes.
- First-half operating cash flow improved by $72.5 million year over year, which management attributed primarily to higher sales and gross profit and lower cash use following Cortrophin Gel’s initial launch period. Investing activities used $9.2 million, mainly for capital expenditures and acquired product rights. Financing activities provided $75.6 million, principally from the share offering.
- ANI ceased Oakville, Ontario operations and completed product transfers to U.S. facilities. The site’s land and building, carried at $8.0 million, were classified as held for sale; no sale timing or proceeds are assured. First-half restructuring expense was $1.1 million.
Outlook, risks, and unusual items
- No specific revenue or earnings guidance is provided in the supplied filing text. Management said available working capital, expected operating cash flows, and borrowing availability should meet requirements and debt obligations for at least 12 months.
- Management noted that favorable sales from supply disruptions affecting competitors may not persist. The business also faces generic competition and price erosion, FDA approval and compliance risks, potential supply interruptions and single-source API dependence, and customer concentration. Four customers each represented at least 10% of Q2 revenue; three customers together accounted for 84% of receivables at quarter-end.
- Debt carries significant interest-rate exposure despite an interest-rate swap; the company reported a 1% rate movement could change interest expense by about $1.4 million on unhedged term debt. Debt is secured by substantially all company and domestic subsidiary assets and is subject to financial covenants.
- ANI reported disclosure controls and procedures were ineffective at June 30, 2023 because remediation of previously identified material weaknesses was ongoing. Management described steps including hiring accounting leadership, adding finance resources, and implementing an ERP system.
- Legal contingencies include appeals in Bystolic antitrust litigation, ranitidine-related claims involving ANI and/or Novitium, and other commercial and regulatory matters. The company says outcomes and potential losses cannot generally be predicted or estimated from the filing; it disputes liability in the matters described.
- Two products and one contract-manufactured product group are marketed without approved NDAs or ANDAs, creating potential enforcement or withdrawal risk. Related revenue was $4.0 million in Q2 and $8.3 million in the first half across the products and contract group described.
- Other notable items: a $2.0 million first-half contingent-consideration fair-value expense; $5.0 million of first-half revenue from revised estimates for prior-period variable consideration; and $0.3 million first-half income-tax benefit. Contingent value rights expired in June without payment.
Investor verification priorities
- Confirm whether Cortrophin Gel growth and product mix can continue to support revenue and margins, and assess the extent of temporary competitor supply shortages.
- Review customer receivable concentration, chargeback and rebate estimates, and returned-goods reserves.
- Track debt interest costs, covenant headroom, available revolver conditions, and use of public-offering proceeds.
- Monitor internal-control remediation and any subsequent assessment of disclosure-control effectiveness.
- Follow developments in ranitidine, Bystolic, and other litigation, as well as regulatory matters affecting unapproved products.